High cholesterol or high blood pressure increases the risk of heart attack, stroke, angina, heart failure and other forms of cardiovascular disease.

Cardiovascular disease: latest news

Cardiovascular disease resources

  • Side effects

    The most common side effects are the result of your body getting used to a new drug. After a few weeks, these side effects usually...

    From: The basics

    Information level Level 1
  • Health checks

    Staff at your HIV clinic use various tests to keep an eye on your health. Many of these tests are done on samples of your...

    From: The basics

    Information level Level 1
  • Other health issues

    As you get older, it’s even more important to regularly attend clinic appointments and stay in touch with your healthcare providers. Your HIV clinic appointments will include...

    From: Booklets

    Information level Level 2
  • Longer-term side-effects

    Effective HIV treatment has significantly reduced the risk of serious kidney disease in people with HIV. However, most anti-HIV drugs can cause some damage to the kidneys,...

    From: Booklets

    Information level Level 2
  • Other blood tests

    Every time you visit your clinic for a check-up you’ll have some blood tests. As well as being used to monitor your CD4 cell count and viral...

    From: Booklets

    Information level Level 2
  • Stroke and HIV

    A stroke is a medical emergency that requires prompt treatment. High blood pressure and raised cholesterol are risk factors for stroke. A healthy diet, regular exercise, stopping smoking, and other...

    From: Factsheets

    Information level Level 2
  • The heart

    Unhealthy lifestyles and untreated HIV contribute to heart attacks, diabetes, stroke and high blood pressure.Symptoms can include tiredness, breathlessness, an irregular heartbeat and chest pains.If anti-HIV drugs...

    From: Factsheets

    Information level Level 2
  • Smoking

    Smoking is one of the most important causes of illness and death in HIV-positive people.Smoking increases the risk of lung cancer, heart disease, high blood...

    From: Factsheets

    Information level Level 2
  • HIV treatment, metabolic changes and ageing

    Smoking, lack of exercise, eating a lot of fatty foods and drinking a lot of alcohol can cause changes to blood fats and to the way your...

    From: Booklets

    Information level Level 2
  • Conditions related to HIV treatment, metabolic changes and ageing

    Lipodystrophy is a condition which causes changes in body shape and involves fat loss or fat gain in certain parts of the body. Long-term use of some older anti-HIV...

    From: Booklets

    Information level Level 2
  • Cholesterol

    Excess cholesterol raises the risk of heart disease and stroke.Diet, exercise and smoking all have an impact on cholesterol levels.Some anti-HIV drugs may raise cholesterol levels....

    From: Factsheets

    Information level Level 2
  • High blood pressure

    You should have your blood pressure monitored regularly as part of your HIV care.HIV drugs can interact with other medicines to affect blood pressure.Blood pressure...

    From: Factsheets

    Information level Level 2
  • Heart disease and antiretroviral therapy

    Cardiovascular disease (disorders of the heart and circulatory system which can lead to heart attack and stroke) is the leading cause of death in the...

    From: HIV treatments directory

    Information level Level 4

Cardiovascular disease features

Cardiovascular disease in your own words

Cardiovascular disease news from aidsmap

More news

Cardiovascular disease news selected from other sources

  • HIV infection may increase heart failure and stroke risk

    A Journal of the American Heart Association analysis of information from a large health insurance database reveals that people living with HIV have an elevated risk of developing cardiovascular disease (CVD), particularly heart failure and stroke. The findings indicate that increased efforts to protect patients' cardiovascular health are needed.

    03 July 2019 | EurekAlert
  • Efavirenz Dose Reduction Improves Lipid Profile in Adults With HIV-1

    The researchers concluded that “a reduced dose of efavirenz (a 400 mg dose is now recommended as an alternative first-line regimen also by [World Health Organization] can lead to a significant decline in total cholesterol and LDL and should be used especially in patients with cardiovascular or metabolic comorbidities.”

    19 June 2019 | Infectious Disease Advisor
  • Performance of CVD Risk Prediction Algorithms in People Living With HIV

    Algorithms may help predict cardiovascular disease (CVD) risk in people living with HIV (PLWHIV), according to a study published in the Journal of Acquired Immune Deficiency Syndromes.

    11 June 2019 | Infectious Disease Advisor
  • American Heart Association Scientific Statement on CVD and HIV

    A new scientific statement from the American Heart Association (AHA) provides "pragmatic" recommendations on how to approach cardiovascular disease (CVD) prevention and management in the growing number of people living with HIV infection.

    04 June 2019 | Medscape (requires free registration)
  • As HIV patients live longer, heart disease might be their next challenge

    As people with HIV live longer, they also find themselves at higher risk for heart attack, stroke and other types of cardiovascular disease. A new American Heart Association report hopes to raise awareness about that connection, along with pointing out cardiovascular disease prevention and treatment strategies for an emerging population with unique concerns researchers have only begun to explore.

    04 June 2019 | American Heart Association
  • Subclinical findings may explain heart failure risk in women with HIV

    Asymptomatic aging women with HIV who are being treated with ART exhibited increased myocardial fibrosis and reduced diastolic function compared with women who are not infected with HIV, according to a study results.

    07 May 2019 | Healio
  • Weight gain with new antiretrovirals: It's complicated

    South Africa’s next big shift in our antiretroviral programme is to replace efavirenz with a newish drug called dolutegravir. The Department of Health is pleased at the prospect of a safer, more robust and, amazingly, cheaper drug. But last year, the first reports surfaced that people using it were gaining weight.

    15 April 2019 | Spotlight
  • TB CAB statement on safety of using bedaquiline and delamanid together

    he Global TB Community Advisory Board (TB CAB) welcomes the important finding from the AIDS Clinical Trials Group Deliberate Trial that newer drugs bedaquiline and delamanid are safe to use together. These findings should erase any remaining reluctance to use these two important drugs together, as the benefits of these safer drugs outweigh the risks--especially for patients with drug-resistant TB who have few other treatment options.

    14 March 2019 | TB Online
  • Experts tackle major cardiovascular issues in treating patients with HIV

    Since the advent of effective antiretroviral therapy (ART), HIV infection has become more like a chronic illness. Now that patients are able to live longer and remain free of developing AIDS, they have begun to encounter new risks from age-related disorders common in the general population, including cardiovascular disease (CVD).

    05 March 2019 | EurekAlert!
  • Stroke Recovery May Be Assisted by HIV Drug, Suggests Study of “Missing” Gene

    Hints have been accumulating that maraviroc, a drug for slowing HIV, could benefit patients who have suffered mild stroke. A few years ago, maraviroc was shown to improve learning and memory in mice. And a new study, also in mice, indicates that the drug enhances motor recovery after stroke and improves cognitive function after traumatic brain injury.

    26 February 2019 | Genetic Engineering & Biotechnology News
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.